Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The clinical study of the safety and efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study

Next Previous
Trial Profile

The clinical study of the safety and efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istaroxime (Primary)
  • Indications Acute heart failure; Decompensated heart failure
  • Focus Proof of concept; Therapeutic Use
  • Sponsors CVie Therapeutics; Lee's Pharmaceutical; Windtree Therapeutics

    • Most Recent Events

    • 06 Apr 2020 According to a Windtree Therapeutics media release, the company presented a new subset analysis from a phase 2b study of istaroxime in patients hospitalized with acute heart failure (AHF) at the American College of Cardiology (ACC) 2020 virtual meeting.
    • 06 Apr 2020 Results published in the Media Release
    • 30 Mar 2020 Results of sub-analysis assessing istaroxime effect on E/e' and stroke volume index in Caucasian and Asian patients treated with istaroxime, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top